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Ferritin Encapsulation of Artificial Metalloenzymes: Engineering a 
Tertiary Coordination Sphere for an Artificial Transfer 
Hydrogenase 
Martina Hestericová, a Tillmann Heinisch, a Markus Lenz b and Thomas R. Ward*a 
Ferritin, a naturally occuring iron-storage protein, plays an 
important role in nanoengineering and biomedical applications. 
Upon iron removal, apoferritin was shown to allow the 
encapsulation of an artificial transfer hydrogenase (ATHase) based 
on the streptavidin-biotin technology. The third coordination 
sphere, provided by ferritin, significantly influences the catalytic 
activity of an ATHase for the reduction of cyclic imines. 
Biocatalysis is an attractive means to prepare high-added value 
products under environmentally benign conditions. Over the 
past few decades, the use of biocatalysis has expanded 
significantly and is now widely applied for the synthesis of 
chemicals, pharmaceuticals, fragrances etc.1 To expand the 
biocatalytic repertoire, artificial metalloenzymes2 (ArMs 
hereafter) have attracted increasing attention.3 
 ArMs, that result from the incorporation of an 
organometallic moiety within a protein or DNA scaffold, 
combine attractive features of both enzymatic and 
homogeneous transition metal catalysis.3,4 To ensure the 
localization of the cofactor within the scaffold, the biotin-
streptavidin technology (biot-Sav hereafter) has found 
widespread use.5 The protein scaffold provides a well-defined 
second coordination sphere around the metal moiety, and 
interacts with the cofactor, the substrates and intermediates. 
Accordingly, it significantly affects the selectivity and reaction 
rate of the ArM.6 
 Inspection of the X-ray structures of various ArM based on 
the biot-Sav technology reveal that the biotinylated cofactor is 
partially solvent-exposed.7 Efforts to genetically engineer the 
biotin-binding vestibule by introduction of various extended 
loops has shown promise.8 Building on our experience with 
mineralizing ArMs within silica nanoparticles,9 we reasoned that 
one may encapsulate an ATHase10 within a hollow protein shell. 
This additional protein environment, which provides a tertiary 
coordination sphere to the ArM11 was anticipated to influence 
the catalytic activity, both in terms of activity and selectivity.  
 Inspection of the size of homotetrameric Sav (4.5 nm · 5.5 
nm · 5.1 nm) led us to hypothesize that ferritin (from horse 
spleen, inner diameter 7-8 nm) may offer an ideal capsule to 
host an ArM (Figure 1).  
 
Fig 1. Apoferritin (indigo cartoon display, PDB code: 5c6f) offers a commensurate hollow 
to encapsulate an artificial metalloenzyme based on the biotin-streptavidin technology 
(Sav, magenta cartoon display, the [Cp*Ir(biot-p-L)Cl] cofactor, blue, is displayed as 
space-filling; PDB code: 3pk2). The model was generated by manually docking the 
ATHase within apoferritin. 
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Herein, we report on our efforts to compartmentalize an 
ATHase based on the biotin-streptavidin technology within 
apoferritin.12 
 Building on our experience with ATHase relying on the 
[Cp*Ir(biot-p-L)Cl] cofactor,13 we set out to encapsulate the 
preassembled ArM [Cp*Ir(biot-p-L)Cl]·Sav within the cavity of 
horse spleen apoferritin. The following Sav mutants pre-
assembled with the biotinylated iridium catalyst were selected 
for encapsulation: [Cp*Ir(biot-p-L)Cl]·S112A Sav (an (R)-
selective imine reductase), [Cp*Ir(biot-p-L)Cl]·S112K Sav (an (S)-
selective imine reductase) and [Cp*Ir(biot-p-L)Cl]·K121A-S112A 
Sav (the most active imine reductase based on the biot-Sav 
complex).9,13a The ATHase was encapsulated within ferritin 
(ATHase@ferritin) by disassembling apoferritin upon 
decreasing the pH < 2.14 Upon increasing the pH to 8, the 
quaternary structure of ferritin is restored, thus allowing to 
encapsulate cargoes that are commensurate with the inner 
diameter of apoferritin. This strategy has been used to 
encapsulate various small molecules, nanoparticles, 
nanocrystals etc.15 To the best of our knowledge however, this 
approach has not been used to encapsulate proteins within 
apoferritin. 
 To highlight the encapsulation of Sav upon reassembly of 
the ferritin cage, we selected Sav equipped with one equivalent 
of a fluorescent biotinylated probe per four free biotin binding 
sites (fbs) of Sav. Accordingly, Sav S112A (tetramer, containing 
four fbs) was preincubated with one equivalent of biotin-4-
fluorescein (B4F hereafter) and added to apoferritin at pH = 2 
(i.e. disassembled apoferritin). Upon increasing the pH to 8, 
B4F·Sav S112A is encapsulated within ferritin (B4F·Sav 
S112A@ferritin hereafter). To remove the unspecifically 
adsorbed B4F·Sav S112A from the outer-surface of apoferritin, 
the solution was treated at pH = 8 with iminobiotin-sepharose 
beads and washed extensively. The iminobiotin moiety binds to 
free biotin-binding sites present in B4F·Sav S112A, thus allowing 
to remove B4F·Sav S112A that is not encapsulated within 
apoferritin by means of centrifugation and filtration. The 
solution that contains B4F·Sav S112A@ferritin was then 
subjected to preparative size-exclusion chromatography (SEC). 
  
 
Fig 2. Preparative size-exclusion chromatogram of B4F·S112A-K121A Sav@ferritin. The 
blue line indicates absorbance at 280 nm. The absorbance at 495 nm (red trace) shows 
that B4F co-elutes with the apoferritin cage at 65 mL (run in 50 mM Tris-HCl, 100 mM 
NaCl, pH 8.0).  
Scheme 1. Reduction of cyclic imines 1a and 1c using the ATHase. 
Fluorescence analysis of the ferritin band unambiguously 
revealed the presence of B4F. As no fluorescence was detected 
upon adding B4F (instead of B4F·Sav) by means of size-exclusion 
chromatography (Figure S1), we hypothesize that B4F·Sav 
S112A@ferritin is formed (Figure 2).  
 Having highlighted the formation of B4F·Sav S112A@ferritin 
by fluorescence, we proceeded to encapsulate various ATHases 
in apoferritin following the same protocol. The resulting 
ATHases [Cp*Ir(biot-p-L)Cl]·S112A@ferritin, [Cp*Ir(biot-p-
L)Cl]·S112K@ferritin and [Cp*Ir(biot-p-L)Cl]·S112A-
K121A@ferritin were purified by preparative SEC (Figure S2).  
The presence of iridium in the purified Sav@ferritin samples 
was confirmed by means of ICP-MS. Upon sample digestion, the  
 Dynamic light scattering (DLS) measurements of the 
combined fractions containing the assembled ferritin shells 
revealed an increase in particle diameter of approx. 20% (Table 
S1). This observation suggests that the ATHase is indeed located 
within ferritin.  
 The presence of the ATHase within the ferritin cage 
[Cp*Ir(biot-p-L)Cl]·Sav@ferritin was further confirmed by 
comparison of the SDS- and native PAGE analysis. Under native 
conditions, the samples containing [Cp*Ir(biot-p-
L)Cl]·Sav@ferritin revealed no band attributable to Sav (Figure 
S3). In contrast, under denaturing conditions, the Sav was 
released from the denatured ferritin cage and could be 
visualized by B4F on the SDS PAGE, as it contained two available 
fbs sites. Due to the remarkable stability of homotetrameric 
Sav, Sav maintained its tetrameric structure and biotin-binding 
activity, even under denaturing SDS PAGE conditions (Figure 
S4). In stark contrast, native PAGE analysis of a 1:1 mixture of 
[Cp*Ir(biot-p-L)Cl]·Sav and apoferritin revealed two bands 
(Figure S4, lane 5). This demonstrates that [Cp*Ir(biot-p-
L)Cl]·Sav is encapsulated within ferritin, rather than 
unspecifically adsorbed on the outer-surface of ferritin, thus 
confirming the DLS observations. 
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Entry Catalysta [Ir] (µM) Sub. ee (%)b, c  conv. (%)b TON 
1 [Cp*Ir(biot-p-L)Cl]  50 1a rac. 16 65 
2 [Cp*Ir(biot-p-L)Cl]  50 1b rac. 18 71 
3 [Cp*Ir(biot-p-L)Cl]·S112A 50 1a 75 35 142 
4 [Cp*Ir(biot-p-L)Cl]·S112A 50 1b 43 39 154 
5 [Cp*Ir(biot-p-L)Cl]·S112K 50 1a -41 25 20 
6 [Cp*Ir(biot-p-L)Cl]·S112K 50 1b 57 6 24 
7 [Cp*Ir(biot-p-L)Cl]·S112A-K121A 50 1a 59 90 358 
8 [Cp*Ir(biot-p-L)Cl]·S112A-K121A 50 1b 69 72 289 
9 [Cp*Ir(biot-p-L)Cl]@ferritin 1.24d 1a 0 0.1 13 
10 [Cp*Ir(biot-p-L)Cl]@ferritin 1.24d 1b 0 5 853 
11 [Cp*Ir(biot-p-L)Cl]·S112A@ferritin 0.42d 1a -46 0.2 74 
12 [Cp*Ir(biot-p-L)Cl]·S112A@ferritin 0.42d 1b 24 5.6 2880 
13 [Cp*Ir(biot-p-L)Cl]·S112K@ferritin 0.40d 1a -47 0.1 46 
14 [Cp*Ir(biot-p-L)Cl]·S112K@ferritin 0.40d 1b 24 5.6 2731 
15 [Cp*Ir(biot-p-L)Cl]·S112A-K121A@ferritin 0.28d 1a -44 0.2 117 
16 [Cp*Ir(biot-p-L)Cl]·S112A-K121A@ferritin 0.28d 1b 20 5.6 3874 
17 S112A-K121A@ferritin 0 1a 0 0 0 
18 S112A-K121A@ferritin 0 1b 0 0 0 
19 Apoferritin 0 1a 0 0 0 
20 Apoferritin 0 1b 0 0 0 
21 Apoferritin + [Cp*Ir(biot-p-L)Cl]·S112A-K121A 50 1a 55 85 340 
22 Apoferritin + [Cp*Ir(biot-p-L)Cl]·S112A-K121A 50 1b 64 69 276 
23 [Cp*Ir(biot-p-L)Cl]·S112A-K121A 1 1a 56 0.4 72 
24 [Cp*Ir(biot-p-L)Cl]·S112A-K121A 1 1b 35 6 1108 
a The reactions were performed using 20 mM substrate concentration at 37°C for 48 h (See Supplementary information 
for experimental details).b Enantiomeric excess and conversion were determined by HPLC analysis. c Positive ee values 
correspond to (R)-product and negative ee values correspond to (S)-product. d Values were calculated based on the [Ir] 
concentration determined by ICP-MS for each encapsulated ATHase batch. 
 
 Next, the encapsulated ATHases were tested for the 
reduction of cyclic imines 1a and 1b (Scheme 1). To determine 
the turnover number of the encapsulated ATHases (TON), ICP-
MS analysis of samples containing Ir as [Cp*Ir(biot-p-
L)Cl]·Sav@ferritin was carried out. The catalytic performance of 
the ATHases [Cp*Ir(biot-p-L)Cl]·Sav@ferritin was compared to 
the corresponding "free" ATHases: [Cp*Ir(biot-p-L)Cl]·Sav.  
 Since the isoquinoline substrates are protonated under the 
reaction conditions,7d they can penetrate through the ferritin 3-
fold channels. In line with this assumption, we observed 
catalysis with all encapsulated ATHases.  
All tested [Cp*Ir(biot-p-L)Cl]·Sav@ferritin, afforded 
preferentially (S)-2a. This contrasts with [Cp*Ir(biot-p-L)Cl]·Sav, 
which affords either (R)-2a or (S)-2a, depending on the Sav 
mutant: i) [Cp*Ir(biot-p-L)Cl]·Sav S112A affords 2a in 75 % ee (R) 
and 35 % conversion (Table 1, entry 3) and [Cp*Ir(biot-p-
L)Cl]·Sav S112K affords 2a in 41 % ee (S) and 20 % conversion 
(Table 1, entry 5). Reduction of imine 1a in the presence of the 
encapsulated [Cp*Ir(biot-p-L)Cl]·S112A Sav@ferritin affords (S)- 
2a in 46 % ee (S) (Table 1, entry 11). 
 Similarly, catalysis with [Cp*Ir(biot-p-L)Cl]·S112A-K121A Sav 
yields 2a in 60 % ee (R) and 90 % conversion (Table 1, entry 7), 
while the encapsulated [Cp*Ir(biot-p-L)Cl]·S112A-K121A 
Sav@ferritin affords (S)-2a in 44 % ee (Table 1, entry 15). 
Control experiments with [Cp*Ir(biot-p-L)Cl]·S112A-K121A Sav 
at 1 µM catalyst loading afforded 56 % ee (R)-2a and 72 TON.  
In the reduction of the less bulky 1b, no inversion of 
enantioselectivity was observed in any of the tested 
encapsulated ATHases. However, the TONs have tripled with 
[Cp*Ir(biot-p-L)Cl]·S112A-K121A Sav@ferritin (entry 16) 
compared to the use of the free ATHase in buffer under similar 
conditions (entry 24). Similar TONs were also obtained for 
[Cp*Ir(biot-p-L)Cl]·S112A@ferritin, which afforded (R)-2b in 24 
% ee and 2880 TON. The [Cp*Ir(biot-p-L)Cl]·S112K@ferritin 
afforded (R)-2b in 24 % ee and 2731 TON.  
The effect on enantioselectivity and catalytic efficiency of the 
encapsulated ATHases depends on both the substrate and the 
used Sav mutant. Further studies in regards to the effect of 
point-mutations on the kinetic behavior of the hybrid catalysts 
are currently undergoing in our research group. 
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Overall, these findings highlight the influence of the third 
coordination sphere on the catalytic performance of the 
ferritin-encapsulated ATHases. 
 Taking advantage of the reversible dissociation and 
reassembly of apoferritin, we have compartmentalized an 
artificial metalloenzyme within a protein cage. The resulting 
ATHases maintained their catalytic activity, displaying up to > 
3800 TON for the reduction of cyclic imines. The marked 
variation in enantioselectivity, observed upon ATHase 
encapsulation, highlights the combined effect of both the 
second- and third coordination sphere provided by Sav and 
ferritin respectively. 
 These results highlight the possibility to encapsulate an ArM 
within ferritin following a reassembly route. The significant 
improvement in TON compared to the free ArM suggests that 
this strategy may offer an attractive means to protect a precious 
metal in a cellular environment and possibly to deliver it in vivo, 
without eliciting an immune response.16 
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